RNTX — Rein Therapeutics Share News
0.000.00%
Last trade - 00:00Aileron Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Aileron Therapeutics Presents Data Demonstrating Alrn-6924’S Activity As Radioprotective Agent In Preclinical Models Of Acute Radiation-Induced Toxicity
Brief: Aileron Therapeutics Announces Presentation Of New Preclinical Data At Upcoming AACR-NCI-EORTC International Conference
U.S. STOCKS ON THE MOVE-IronNet, ION Geophysical, Offerpad Solutions
Aileron rises on promising new data from chemoprotective drug study
Brief: Aileron Therapeutics Presents New Clinical Data For ALRN-6924 at ESMO Virtual Congress 2021
Brief: Aileron Therapeutics To Present New Clinical Data At ESMO 2021 Supporting Chemoprotective Agent Alrn-6924
Brief: Aileron Therapeutics Presents Initial Findings From Ongoing Study Of ALRN-6924
Brief: Aileron Therapeutics Posts Quarterly Loss Per Share Of $0.06
Aileron Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Aileron Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview
Aileron Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview
Aileron Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Aileron Therapeutics Announces Initiation Of Randomized, Double-Blind, Placebo-Controlled Trial Of ALRN-6924 In Patients With Advanced Non-Small Cell Lung Cancer
Brief: Aileron Therapeutics To Be Added To The Russell Microcap® Index
Aileron Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Aileron Therapeutics Reports First Quarter 2021 Financial Results And Provides Business Update
Brief: Aileron Therapeutics Reports Fourth Quarter And Full Year 2020 Financial Results And Provides Business Highlights
Brief: Aileron Therapeutics Announces Enrollment Expansion For Upcoming Phase 1B Clinical Trial Of ALRN-6924 In Patients With Advanced Non-Small Cell Lung Cancer